Congress

Pharmalot

Pharmalittle: House progressives seek to change Pelosi bill; shortage of a critical cancer drug for kids

By Ed Silverman

Politics

House progressives plot overhaul of Pelosi drug pricing bill

By Lev Facher and Nicholas Florko

Pharmalot

Most Americans back various ideas to lower drug costs, but some fear impeachment will get in the way

By Ed Silverman

Pharmalot

Pharmalittle: Sackler role in opioid crisis to be debated in court; J&J legal strategy shows risks

By Ed Silverman

First Opinion

PhRMA’s talking points shouldn’t derail the Pelosi drug pricing bill

By Peter B. Bach

First Opinion

We need benchmarking, not arbitration, to quell surprise medical billing

By James Rickert

Pharmalot

Pharmalittle: Did you notice this drug pricing bill to save $3b? state AGs say Purdue shouldn’t pay bonuses

By Ed Silverman

Politics

‘It shows how much pharma has on their plate’: Congress just quietly passed a bill that will cost drug makers $3 billion

By Nicholas Florko

Politics

An unconventional health care speech: Trump wishes pharma stocks would drop, and implies drug industry is behind impeachment

By Nicholas Florko

Politics

Pelosi’s drug pricing plan could wipe out some key funding for low-income hospitals

By Nicholas Florko

First Opinion

The industry that cries wolf: pharma and innovation

By Michael A. Carrier and Genevieve Tung

Politics

‘Why don’t you stop talking?’ Hearing on Pelosi’s drug pricing plan mired by partisan bickering

By Nicholas Florko

Politics

The Democrats shepherding Pelosi’s drug pricing bill have taken plenty of campaign cash from pharma

By Lev Facher

Speaker Pelosi Introduces Flagship Prescription Drug Costs Bill

First Opinion

Patients will be the losers as Pelosi’s plan to control drug prices nearly strikes out

By Peter Kolchinsky

Politics

Trump says it’s ‘great to see’ Pelosi’s drug pricing plan

By Lev Facher and Nicholas Florko

Politics

Our 9 biggest questions about Nancy Pelosi’s drug pricing bill

By Nicholas Florko and Lev Facher

Politics

Pelosi’s drug pricing plan would let Medicare negotiate prices for up to 250 drugs

By Lev Facher

Politics

Democrats still have questions about Nancy Pelosi’s drug pricing plan

By Lev Facher

Politics

With ominous TV spots and a senior ‘strike force,’ AARP launches an all-out attack on pharma

By Nicholas Florko

Politics

Pelosi’s drug pricing plan is more aggressive than expected

By Nicholas Florko and Lev Facher

Pharmalot

Pharmalittle: Some states object to Purdue opioid deal; top pharma CEOs donate to key Republicans

By Ed Silverman

Politics

As Congress considers lowering drug costs, pharma CEOs target key senators with campaign cash

By Lev Facher

Pharmalot

AIDS activists say Gilead put profits over patients — and misled Congress about an HIV pill

By Ed Silverman

Politics

Despite their pledges, Democrats haven’t yet lowered drug prices. Here’s how they’re explaining themselves

By Nicholas Florko

Pharmalot

Sanders and Cummings renew probe into generic pricing they say was ‘stonewalled’

By Ed Silverman

After 10 hours and a pile of rejected amendments, Democrats advance their drug pricing bill out of two key committees

Pelosi: Democrats will name marquee drug pricing bill for late Rep. Cummings

Pelosi’s drug pricing plan puts medical innovation at risk

CBO estimate on Pelosi drug bill misses its long-term impact on health

Pharmalittle: House progressives seek to change Pelosi bill; shortage of a critical cancer drug for kids

House progressives plot overhaul of Pelosi drug pricing bill

Most Americans back various ideas to lower drug costs, but some fear impeachment will get in the way

Pharmalittle: Sackler role in opioid crisis to be debated in court; J&J legal strategy shows risks

PhRMA’s talking points shouldn’t derail the Pelosi drug pricing bill

We need benchmarking, not arbitration, to quell surprise medical billing

Pharmalittle: Did you notice this drug pricing bill to save $3b? state AGs say Purdue shouldn’t pay bonuses

‘It shows how much pharma has on their plate’: Congress just quietly passed a bill that will cost drug makers $3 billion

An unconventional health care speech: Trump wishes pharma stocks would drop, and implies drug industry is behind impeachment

Pelosi’s drug pricing plan could wipe out some key funding for low-income hospitals

The industry that cries wolf: pharma and innovation

‘Why don’t you stop talking?’ Hearing on Pelosi’s drug pricing plan mired by partisan bickering

The Democrats shepherding Pelosi’s drug pricing bill have taken plenty of campaign cash from pharma

Patients will be the losers as Pelosi’s plan to control drug prices nearly strikes out

Trump says it’s ‘great to see’ Pelosi’s drug pricing plan

Our 9 biggest questions about Nancy Pelosi’s drug pricing bill

Pelosi’s drug pricing plan would let Medicare negotiate prices for up to 250 drugs

Democrats still have questions about Nancy Pelosi’s drug pricing plan

With ominous TV spots and a senior ‘strike force,’ AARP launches an all-out attack on pharma

Pelosi’s drug pricing plan is more aggressive than expected

Pharmalittle: Some states object to Purdue opioid deal; top pharma CEOs donate to key Republicans

As Congress considers lowering drug costs, pharma CEOs target key senators with campaign cash

AIDS activists say Gilead put profits over patients — and misled Congress about an HIV pill

Despite their pledges, Democrats haven’t yet lowered drug prices. Here’s how they’re explaining themselves

Sanders and Cummings renew probe into generic pricing they say was ‘stonewalled’